Angina Pectoris Drugs Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Angina Pectoris Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Angina Pectoris Drugs Market:
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

According to The Business Research Company’s Angina Pectoris Drugs Global Market Report 2024, The angina pectoris drugs market size has grown strongly in recent years. It will grow from $11.82 billion in 2023 to $12.47 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high prevalence of cardiovascular diseases, aging population demographics, lifestyle factors, increase in hypertension rates, diabetes prevalence ..

The angina pectoris drugs market size is expected to see strong growth in the next few years. It will grow to $15.48 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising global obesity rates, advancements in precision medicine, focus on preventive cardiology, patient education initiatives, research on novel therapeutic targets .. Major trends in the forecast period include telemedicine for remote monitoring, real-world evidence and outcome studies, patient-centric medication education, strategic alliances for market access, regulatory advances and expedited approvals..

The increasing prevalence of chronic angina pectoris is expected to propel the growth of the angina pectoris drug market going forward. Chronic angina pectoris is chest pain or discomfort caused by reduced blood flow to the heart muscle. Angina pectoris drugs are vital in treating chronic angina. They can provide several benefits to those suffering from this illness, including coronary heart disease, cardiovascular disease, high blood pressure, and being overweight or obese. For instance, in May 2023, according to the Centers for Disease Control and Prevention Highlights, a US-based intergovernmental organization, coronary heart disease killed round 375,476 people in 2021 where, roughly one in every twenty people aged 20 and over (5%). Further, in 2021, almost 2 out of every 10 deaths from coronary artery disease are expected to occur in people under 65. Furthermore, in December 2022, according to the National Library of Medicine, a national center for biological information, Angina affects more than 10 million people in the United States, with more than 500,000 new diagnoses each year. Therefore, the increasing prevalence of chronic angina pectoris is driving the growth of the angina pectoris drug market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

The angina pectoris drugs market covered in this report is segmented –

1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Product innovation is a key trend gaining popularity in angina pectoris drugs market. Major companies operating in the angina pectoris drug market are adopting new technologies to sustain their position in the market. For instance, in March 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Labetalol Hydrochloride Injection, USP, in a prefilled syringe. The Food and Drug Administration of the United States has authorized this product. In hospitals, 10 mg/2 mL PFS is used to treat severe hypertension and lower blood pressure.

The angina pectoris drugs market report table of contents includes:

1. Executive Summary
2.Angina Pectoris Drugs Market Characteristics
3. Angina Pectoris Drugs Market Trends And Strategies
4. Angina Pectoris Drugs Impact On Market Analysis
5. Angina Pectoris Drugs Market Size And Growth
6. Angina Pectoris Drugs Segmentation
7.Angina Pectoris Drugs Regional And Country Analysis
.
.
.
27. Angina Pectoris Drugs Competitive Landscape And Company Profiles
28.Angina Pectoris Drugs Key Mergers And Acquisitions
29.Angina Pectoris Drugs Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

• Medtronic PLC
• Synvisc Micro Companies Alliance Inc.
• B. Braun Melsungen AG
• Novare Surgical Systems Inc.
• Dextera Surgical Inc.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model